HDA7 Inhibitors
Chemical inhibitors of HDA7 employ various molecular mechanisms to impede its function. Trichostatin A, for instance, binds directly to the enzyme, thereby increasing the acetylation levels of histones and preventing the enzyme from exerting its gene silencing effects. Similarly, Suberoylanilide hydroxamic acid (SAHA), also known as Vorinostat, targets the catalytic site of HDA7, obstructing its ability to remove acetyl groups from histones. This action results in an open chromatin structure conducive to gene expression. Another inhibitor, Valproic acid, competes with acetyl-coenzyme A at the catalytic domain of HDA7, leading to hyperacetylation of histones. Sodium butyrate also interacts with the catalytic site of HDA7, which leads to a transcriptionally active chromatin configuration.
Entinostat, a benzamide histone deacetylase inhibitor, selectively binds to HDA7, while Romidepsin, a cyclic peptide, chelates the Zn2+ ion in the active site of HDA7, essential for its activity. Panobinostat, a broad-spectrum HDAC inhibitor, non-selectively binds to HDA7 among other HDACs, inhibiting their deacetylase activity. Belinostat, another hydroxamate-type inhibitor, targets multiple HDAC enzymes including HDA7 by binding to their zinc-binding domains. Chidamide, a selective class I HDAC inhibitor, binds to the enzyme's active site and impedes its function. Mocetinostat, which inhibits class I and IV HDACs, exerts its effect by binding to HDA7, leading to an increase in histone acetylation. Givinostat, similar to other hydroxamate-based inhibitors, interacts with the catalytic domain of HDA7, while Tacedinaline, an acetamide derivative, inhibits HDA7 by binding to its catalytic site. These interactions between chemical inhibitors and HDA7 culminate in the inhibition of the enzyme's ability to deacetylate histone proteins, thus affecting the chromatin structure.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor which leads to increased acetylation of histones. HDA7, being a histone deacetylase, is directly inhibited by Trichostatin A's action, which prevents it from deacetylating histones, thus maintaining a hyperacetylated state of chromatin that is less conducive to gene silencing. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA, also known as Vorinostat, directly inhibits histone deacetylases like HDA7 by binding to the catalytic site of the enzyme. This prevents HDA7 from removing acetyl groups from histone tails, thereby inhibiting its gene silencing activity. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid is a short-chain fatty acid that inhibits histone deacetylases such as HDA7. It directly competes with acetyl-coenzyme A and binds to the catalytic domain of HDA7, which inhibits its deacetylase activity leading to hyperacetylation of histones. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate acts as a histone deacetylase inhibitor by directly interacting with the catalytic site of HDA7, inhibiting its ability to deacetylate histone proteins and thus promoting a more open and transcriptionally active chromatin structure. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat is a benzamide histone deacetylase inhibitor that specifically inhibits class I HDACs, including HDA7. It binds to the active site of HDA7, preventing it from deacetylating histones and thus inhibiting its activity. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin is a cyclic peptide that inhibits histone deacetylases. It chelates Zn2+ in the active site of HDA7, which is essential for its deacetylase activity. This results in the inhibition of HDA7's ability to remove acetyl groups from histones. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is a hydroxamic acid-derived histone deacetylase inhibitor that non-selectively binds to and inhibits the deacetylase activity of HDACs, including HDA7, thereby preventing the deacetylation of histone proteins. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat is a hydroxamate-type histone deacetylase inhibitor that inhibits several HDAC enzymes, including HDA7. It binds to the zinc-binding domain of HDA7, leading to inhibition of its enzymatic activity. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $62.00 $250.00 $1196.00 | ||
Chidamide is a benzamide chemical that selectively inhibits class I HDACs, such as HDA7. It directly binds to the enzyme's active site and inhibits its deacetylase function, resulting in increased histone acetylation. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat is a benzamide derivative that inhibits class I and IV histone deacetylases, including HDA7. It binds to and inhibits the deacetylase activity of HDA7, leading to hyperacetylation of histones. | ||||||